Loading organizations...
Pharmaron operates as a comprehensive contract research, development, and manufacturing organization (CRDMO) for the global life sciences industry. It provides integrated, end-to-end services across the entire drug discovery and development lifecycle, from early research through preclinical and clinical phases to commercial manufacturing. Its platforms encompass specialized laboratory services (chemistry, biology, DMPK) and Chemistry, Manufacturing & Controls (CMC) solutions for diverse therapeutic modalities.
Dr. Boliang Lou founded Pharmaron in 2004, serving as its Chairman and CEO. With a Ph.D. in Chemistry and extensive leadership in pharmaceutical R&D at companies like Exelixis, Dr. Lou recognized the industry's need for a unified, high-quality service provider. His founding insight focused on streamlining the complex drug development process through an integrated platform.
Pharmaron partners with pharmaceutical, biotechnology, and medical device companies, offering critical support to advance their pipelines. The company's vision is to accelerate the delivery of innovative medicines to patients worldwide by providing comprehensive, efficient solutions across the drug development value chain.
Pharmaron has raised $320.0M across 2 funding rounds.
Key people at Pharmaron.
Pharmaron was founded in 2004 by Boliang Lou (Founder, Chairman, CEO).
Pharmaron has raised $320.0M in total across 2 funding rounds.
Pharmaron was founded in 2004 by Boliang Lou (Founder, Chairman, CEO).
Pharmaron has raised $320.0M in total across 2 funding rounds.
Pharmaron's investors include yongwu fan, Richard Li, DCM, Jeffrey Li, Legend Capital.
Key people at Pharmaron.
Pharmaron is a global contract research and development and manufacturing organization (CRO/CDMO) that provides end‑to‑end drug discovery, preclinical, clinical and commercial manufacturing services for small molecules, biologics and cell & gene therapies[4][5]. Pharmaron positions itself as a partner to pharmaceutical and biotech companies, offering integrated chemistry, biology, DMPK, bioanalysis, CMC and clinical services at scale across facilities in China, the U.S. and the U.K.[3][5].
High‑Level Overview
For a portfolio‑company style summary (Pharmaron as an operating company)
Origin Story
Core Differentiators
Role in the Broader Tech / Life‑Sciences Landscape
Quick Take & Future Outlook
Quick take: Pharmaron’s combination of scale, integrated modality coverage and lab‑level enabling technology positions it as a major global CRO/CDMO that helps biopharma companies outsource complex discovery‑to‑commercial workflows and accelerate time to clinic and market[4][6].[4]
Pharmaron has raised $320.0M across 2 funding rounds. Most recently, it raised $280.0M Other Equity in December 2015.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Nov 19, 2020 | Imago BioSciences, Inc. | $80.0M Series C | Farallon Capital Management | Amgen Ventures, BlackRock, Blackstone, Frazier Healthcare Partners, Greenspring Associates, Irving Investors, Kingdon Capital, MRL Ventures Fund, Omega Funds, Surveyor Capital, T. Rowe Price Associates, Xeraya Capital |
| Mar 21, 2019 | Imago BioSciences, Inc. | $40.0M Series B | Dina Chaya | Amgen Ventures, Patrick Heron, Greenspring Associates, MRL Ventures Fund |
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 11, 2015 | $280.0M Other Equity | yongwu fan, Richard Li | |
| Feb 1, 2011 | $40.0M Series C | DCM, DCM, Jeffrey Li, Legend Capital |